Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	e of entity	ABN/ARSN		
Sigi	na Pharmaceuticals Limited		15 088 417 403	
We	(the entity) give ASX the following	g information.		
Inf	ormation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX	1	3D dated 2 October	
	al of all shares/units bought e been received, before, and		-	
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to	94,651,129	250,000	
	which acceptances have been received			
4	Total consideration paid or payable for the shares/units	\$67,975,080	\$191,200	

		Before previous day		s day	Previous day	
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.7700	
		Lowest \$0.5600	price	paid:	Lowest price paid: \$0.7450 Highest price allowed under rule 7.33: \$0.7865	

How many shares/units may still be bought back?

6	If the company/trust has disclosed						
	an intention to buy back a						
	maximum number of shares/units						
	- the remaining number of						
	shares/units to be bought back						

23,729,223			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 21 October 2014

(Director/Company secretary)

Print name: SUE MORGAN

== == == == ==